Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome - PubMed (original) (raw)
Comparative Study
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome
Q Zhang et al. Proc Natl Acad Sci U S A. 1996.
Abstract
Signaling through the interleukin 2 receptor (IL-2R) involves phosphorylation of several proteins including Jak3, STAT5, and, in preactivated cells, STAT3. In the present study, we examined the functional status of the IL-2R-associated Jak/STAT pathway in malignant T lymphocytes from advanced skin-based lymphomas: anaplastic large T-cell lymphoma (ALCL) and Sezary syndrome (SzS). Proliferation of three ALCL cell lines (PB-1, 2A, and 2B) was partially inhibited by rapamycin, a blocker of some of the signals mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated by the T-cell receptor. All the cell lines expressed on their surface the high-affinity IL-2R (alpha, beta, and gamma c chains). They showed basal, constitutive phosphorylation, and coassociation of Jak3, STAT5, and STAT3. Weak basal phosphorylation of IL-2R gamma c was also detected. In regard to SzS, peripheral blood mononuclear cells from 10 of 14 patients showed basal phosphorylation of Jak3, accompanied by phosphorylation of STAT5 in 9 patients, and STAT3 in 4 patients. However, in vitro overnight culture of SzS cells without exogenous cytokines resulted in markedly decreased Jak3 and STAT5 phosphorylation, which could be reversed by stimulation with IL-2. This indicates that the basal phosphorylation of Jak3 and STAT5 in freshly isolated SzS cells is induced rather than constitutive. The basal activation of the Jak/STAT pathway involved in IL-2R signal transduction in ALCL and SzS cells reported here suggests that this pathway may play a role in the pathogenesis of cutaneous T-cell lymphomas, although the mechanism (induced versus constitutive) may vary between different lymphoma types.
Similar articles
- Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q, Lee B, Korecka M, Li G, Weyland C, Eck S, Gessain A, Arima N, Lessin SR, Shaw LM, Luger S, Kamoun M, Wasik MA. Zhang Q, et al. Leuk Res. 1999 Apr;23(4):373-84. doi: 10.1016/s0145-2126(98)00173-8. Leuk Res. 1999. PMID: 10229324 - Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine.
Wasik MA, Nowak I, Zhang Q, Shaw LM. Wasik MA, et al. Leuk Lymphoma. 1998 Feb;28(5-6):551-60. doi: 10.3109/10428199809058363. Leuk Lymphoma. 1998. PMID: 9613985 - Cytokines: shared receptors, distinct functions.
DiSanto JP. DiSanto JP. Curr Biol. 1997 Jul 1;7(7):R424-6. doi: 10.1016/s0960-9822(06)00208-9. Curr Biol. 1997. PMID: 9210372 Review. - Down-modulation of IL-2-triggered JAK3-STAT5 signaling following CD4-ligand binding.
Lowry RP, Goebel J. Lowry RP, et al. Transplant Proc. 1999 Feb-Mar;31(1-2):820-1. doi: 10.1016/s0041-1345(98)01787-4. Transplant Proc. 1999. PMID: 10083356 Review. No abstract available.
Cited by
- Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.
Krejsgaard T, Litvinov IV, Wang Y, Xia L, Willerslev-Olsen A, Koralov SB, Kopp KL, Bonefeld CM, Wasik MA, Geisler C, Woetmann A, Zhou Y, Sasseville D, Odum N. Krejsgaard T, et al. Blood. 2013 Aug 8;122(6):943-50. doi: 10.1182/blood-2013-01-480889. Epub 2013 Jun 25. Blood. 2013. PMID: 23801634 Free PMC article. - Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.
Poglio S, Prochazkova-Carlotti M, Cherrier F, Gros A, Laharanne E, Pham-Ledard A, Beylot-Barry M, Merlio JP. Poglio S, et al. Leukemia. 2021 Jun;35(6):1696-1709. doi: 10.1038/s41375-020-01068-2. Epub 2020 Oct 26. Leukemia. 2021. PMID: 33106625 Free PMC article. - Immunopathogenesis and therapy of cutaneous T cell lymphoma.
Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Kim EJ, et al. J Clin Invest. 2005 Apr;115(4):798-812. doi: 10.1172/JCI24826. J Clin Invest. 2005. PMID: 15841167 Free PMC article. Review. - Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. Turkson J, et al. Mol Cell Biol. 1999 Nov;19(11):7519-28. doi: 10.1128/MCB.19.11.7519. Mol Cell Biol. 1999. PMID: 10523640 Free PMC article. - Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.
O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F. O'Shea JJ, et al. J Clin Immunol. 1997 Nov;17(6):431-47. doi: 10.1023/a:1027388508570. J Clin Immunol. 1997. PMID: 9418183 Review.
References
- J Invest Dermatol. 1983 Nov;81(5):392-7 - PubMed
- Annu Rev Immunol. 1995;13:369-98 - PubMed
- Blood. 1985 Aug;66(2):358-66 - PubMed
- J Clin Pathol. 1987 Sep;40(9):995-1015 - PubMed
- Am J Pathol. 1990 Feb;136(2):383-90 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous